04-05-2025
Idexx Laboratories price target raised to $460 from $420 at Stifel
Stifel raised the firm's price target on Idexx Laboratories (IDXX) to $460 from $420 and keeps a Hold rating on the shares. The firm says that the company's Q1 results were not surprising, but the stock's reaction was a bit stronger than expected. Stifel will continue to monitor the uptake of Cancer Dx and inVue, but for now the firm believes the near-term contribution is already reflected in estimates.
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today's best-performing stocks on TipRanks >>
Read More on IDXX:
Disclaimer & DisclosureReport an Issue
Early notable gainers among liquid option names on May 1st
Idexx Laboratories: Stable Performance and Growth Potential Amid Market Challenges
Idexx Laboratories reports Q1 EPS $2.96, consensus $2.84
Idexx Laboratories raises 2025 EPS view 19c to $11.93-$12.43, consensus $11.99
Is IDXX a Buy, Before Earnings?
